Merck + Co., Inc.

Other

Banyu Pharmaceutical Co. Ltd

Merck Sharp + Dohme Corp.

David M Tschaen

Richard D Tillyer

Paul N Devine

Ulf H Dolling

Ralph P Volante

Zhiguo Jake Song

Lisa F Frey

Mangzu Zhao

Richard Desmond

Takehiko Iida

Richard M Heid, Jr

Kenji Maeda

Thomas R Verhoeven

Toshiaki Mase

Steven A Weissman

Ichiro Shinkai

Shinji Kato

Michel M Chartrain

Toshihiro Wada

Jing Li

Matthew Heileman

Hiroki Sato

Kenichi Asakawa

Yoshiaki Kato

Sander G Mills

Masashi Kawasaki

Joseph E Lynch

Feng Xu

Guy R Humphrey

David Askin

Robert A Reamer

Gang Qian

William L Laswell

Todd K Jones

Ioannis N Houpis

Dongwei Cai

Michel Journet

Eiichi Mano

F Edward Roberts

Donald R Gauthier

Yao-Jun Shi

Yang Cao

Tetsuji Itoh

Ilias K Dorziotis

Barbara Ann Krulewicz

Benjamin D Sherry

Shouichi Hiraga

Asayuki Kamatani

Pamela M Simpson

Jayanthi Reddy

Ben Marcune

Charles Boudreau

Fengrui Lang

The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase and HIV replication, and the treatment of human immunodeficiency virus infection in humans.

Process for making reverse transcriptase inhibitors

This invention relates to a process for making spirolactone compounds analogous to formula I. 

Process for making spirolactone compounds

This invention relates to a process for making spirolactone compounds analogous to formula I 

This invention relates to processes for making spirolactone compounds analogous to formula I:

The present invention relates to a novel process to make indolocarbazole glycosides in high purity which inhibit the growth of tumor cells and are therefore useful in the treatment of cancer in mammals, and the like.

Preparation and isolation of indolocarbazole glycosides

Michael addition conducted in the presence of a zinc-amine complex and additional amounts of the amine component results in product with high diastereomeric excess.

Diastereoselective preparation of Michael adducts

This invention relates to a key intermediate in the synthesis of an endothelin antagonist the synthesis of this key intermediate via an asymmetric conjugate addition reaction.

Asymmetric conjugate addition reaction

This invention relates to a key intermediate in the synthesis of an endothelin antagonist and the synthesis of this key intermediate using an asymmetric conjugate addition reaction.

The present invention relates to a periodic acid oxidation which converts the penultimate intermediate bearing a primary alcohol to the target endothelin antagonist compound of Formula I having a carboxylic acid.

Oxidation process using periodic acid

The present invention relates to an oxidation which converts a primary or secondary alcohol of Formula II: ##STR1## to an acid or ketone of Formula I: ##STR2## with periodic acid and a catalytic amount of a chromium reagent.

The present invention relates to a TEMPO-catalyzed oxidation of primary alcohols, RCH.sub.2 OH to corresponding carboxylic acids, RCOOH in the presence of catalytic in the presence of catalytic amount of NaClO and stoichiometric amount of NaClO.sub.2 as an oxidant. ##STR1##

Oxidaton of primary alcohols to carboxylic acids with a TEMPO catalyst

The invention relates to a class of enantiomerically pure intermediates represented by Formula I, where X is F, Cl, Br, or I, and a novel enantioselective bioreductive process using yeast to form these intermediates, which are useful in the synthesis of endothelin antagonists, and the like. ##STR1##

Enantioselective bioreduction using yeast

This invention relates to a cyclization process useful in the preparation of a key intermediate in the preparation of an endothelin antagonist of the general formula shown below: ##STR1##

Phosphate-mediated cyclization

The present invention relates to an oxidation using sodium chlorite in the presence of a catalytic amount of TEMPO and sodium hypochlorite which converts the penultimate intermediate bearing a primary alcohol to the target endothelin antagonist compound of Formula I having a carboxylic acid ##STR1##

Oxidation process using tempo

Pyridine propanoic acid derivatives

Growing community of inventors

Holmdel, NJ, United States of America

David M Tschaen